🇺🇸 FDA
Patent

US 9616015

Formulations of human tissue kallikrein-1 for parenteral delivery and related methods

granted A61KA61K38/4853A61K9/0019

Quick answer

US patent 9616015 (Formulations of human tissue kallikrein-1 for parenteral delivery and related methods) held by DiaMedica Inc. expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
DiaMedica Inc.
Grant date
Tue Apr 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K38/4853, A61K9/0019, A61P, A61P3/10